statements

Beta Drugs Ltd.

NSE: BETA

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,315.60+38.4 (+1.69%)

24 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Beta Drugs Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30

Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	3.13	1.38	0.26	26.38	41.65	65.93	90.81	116.12	183.84	227.11	295.71	362.36	384.83	410.17
Cost of Operating Revenue	2.56	0.94	0.24	16.37	25.03	44.22	58.45	79.06	119.50	140.39	190.98	224.49	188.33	193.73
Gross Profit	0.57	0.44	0.02	10.01	16.63	21.71	32.36	37.07	64.34	86.72	104.73	137.87	196.49	216.44
Gross Margin	18.1	32.1	7.4	37.9	39.9	32.9	35.6	31.9	35.0	38.2	35.4	38.0	51.1	52.8
Total Operating Expenses	2.97	1.28	0.35	24.60	35.68	56.92	76.56	98.24	148.39	184.08	245.58	300.26	326.30	344.60
Operating Profit	0.16	0.11	-0.09	1.78	5.97	9.01	14.25	17.88	35.45	43.03	50.13	62.09	58.53	65.57
Operating Margin	5.0	7.6	-35.0	6.7	14.3	13.7	15.7	15.4	19.3	18.9	17.0	17.1	15.2	16.0
Financing Income/(Expense) - Net	-0.11	-0.09	-0.02	-0.66	-0.82	-1.22	-2.38	-2.09	-1.40	-2.06	-1.65	-1.88	-15.31	-14.55
Profit before Taxes	0.04	0.02	-0.11	1.13	5.18	7.91	11.97	15.95	34.30	41.06	48.75	61.54	54.39	60.79
Income Taxes	-	-	-	-	-	-0.13	2.56	4.23	9.47	10.34	12.32	14.55	12.91	14.52
Profit after Tax	0.04	0.02	-0.11	1.13	5.18	8.04	9.42	11.72	24.83	30.72	36.44	42.42	41.48	45.59
PAT Margin	1.4	1.6	-43.5	4.3	12.4	12.2	10.4	10.1	13.5	13.5	12.3	11.7	10.8	11.1
EPS - Basic - ex Extraordinary Items	0.05	0.02	-0.13	1.25	5.70	8.85	9.33	11.61	24.60	30.43	36.10	46.55	40.92	44.21
EPS - Diluted - ex Extraordinary Items	0.05	0.02	-0.13	1.25	5.70	8.85	9.33	11.61	24.60	30.43	36.10	46.55	40.92	44.21
EBIT	0.16	0.11	-0.09	1.78	5.97	9.01	14.25	17.88	35.45	43.03	50.13	62.09	58.53	65.57
EBITDA	0.25	0.19	0.01	3.02	7.21	11.85	18.01	24.76	42.70	53.44	59.91	74.61	75.68	83.34
EBITDA Margin	8.1	13.7	2.5	11.4	17.3	18.0	19.8	21.3	23.2	23.5	20.3	20.6	19.7	20.3

Balance Sheet

Abridged

Understanding Balance Sheet

Beta Drugs Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1.03	0.70	1.69	7.80	16.21	45.43	56.04	68.04	96.96	127.68	177.87	331.08	335.16
Long-Term Investments	-	-	-	-	-	0.35	0.35	0.78	0.78	0.78	-	-	17.96
Property Plant & Equipment - Net	0.73	0.64	6.25	7.34	8.12	32.36	40.34	39.26	50.67	58.09	59.20	80.36	115.37
Total Non-Current Assets	0.74	0.66	6.32	7.40	8.33	37.11	51.14	49.46	60.89	70.74	76.23	105.16	160.64
Total Assets	1.77	1.36	8.01	15.20	24.54	82.54	107.18	117.51	157.85	198.42	254.10	436.23	495.80
Total Current Liabilities	0.95	0.67	3.00	9.04	13.27	32.41	36.69	33.30	48.97	63.02	84.67	102.73	108.14
Long Term Debt	0.61	0.51	3.94	3.90	3.76	7.36	10.28	11.13	11.83	6.97	6.04	126.99	133.32
Total Non-Current Liabilities	0.61	0.51	3.94	3.96	3.89	9.21	13.37	15.59	16.54	12.52	12.31	136.41	142.89
Total Liabilities	1.55	1.17	6.94	13.00	17.16	41.62	50.06	48.89	65.51	75.54	96.98	239.14	251.03
Total Shareholders' Equity	0.21	0.18	1.07	2.20	7.38	40.92	57.11	68.61	92.34	122.88	157.12	197.10	244.77
Total Equity	0.21	0.18	1.07	2.20	7.38	40.92	57.11	68.61	92.34	122.88	157.12	197.10	244.77
Total Liabilities & Equity	1.77	1.36	8.01	15.20	24.54	82.54	107.18	117.51	157.85	198.42	254.10	436.23	495.80

Cash Flow

Abridged

Understanding Cash Flow Statement

Beta Drugs Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	0.15	0.05	-0.01	2.18	5.33	9.47	12.03	20.41	37.95	41.32	42.77	53.29	58.82
Working Capital - Increase/(Decrease)	-0.26	0.08	1.38	-3.17	-3.06	-10.55	-5.96	-3.89	-9.77	-19.69	-13.58	-19.03	-26.99
Net CF from Operating Activities	-0.11	0.13	1.37	-0.99	2.27	-1.08	6.07	16.51	28.18	21.63	29.19	34.27	31.84
Capital Expenditures - Net	0.03	-	5.71	2.32	2.03	20.67	15.30	5.76	19.43	18.21	11.62	36.86	53.48
Net CF from Investing Activities	-0.03	-	-5.71	-2.32	-2.03	-21.02	-15.30	-6.18	-22.21	-19.73	-15.06	-40.83	-61.25
Stock - Issuance/(Retirement) - Net	-	-	1.00	-	-	-	0.96	-	-	-	-	0.48	0.04
Debt - LT & ST - Issuance/(Retirement) - Total	0.15	-0.13	3.39	3.38	-0.23	13.50	2.57	-5.29	1.82	-0.06	-4.67	124.47	0.32
Net Cash Flow from Financing Activities	0.15	-0.13	4.39	3.38	-0.23	13.50	11.31	-5.29	0.93	-0.06	-4.67	124.95	7.24
Free Cash Flow to Equity	0.00	0.00	-0.95	0.07	0.02	-8.25	-6.66	5.46	10.57	3.36	12.91	121.88	-21.33
Free Operating CF net dividend	-0.15	0.13	-4.34	-3.31	0.24	-21.75	-9.23	10.76	8.75	3.42	17.58	-2.59	-21.65
Free Operating CF	-0.15	0.13	-4.34	-3.31	0.24	-21.75	-9.23	10.76	8.75	3.42	17.58	-2.59	-21.65

Business Segment Analysis

FY End:

Mar 25

Beta Drugs Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing of Oncology medicines (100.0%)₹ 36.86 Cr

Revenue / Sales

Manufacturing of Oncology medicines (100.0%)₹ 362.36 Cr

Assets

Manufacturing of Oncology medicines (100.0%)₹ 436.23 Cr

Operating Income

Manufacturing of Oncology medicines (100.0%)₹ 62.09 Cr

Regional Segment Analysis

FY End:

Mar 25

Beta Drugs Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (43.8%)₹ 282.87 CrIndia (43.8%)₹ 282.87 CrExport (12.3%)₹ 79.48 Cr

Historical Segment Analysis

Track how Beta Drugs Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacturing of Oncology medicines	21	15	6	19	18	12	37

Frequently Asked Questions

What is the revenue of Beta Drugs Ltd.?

The latest trailing twelve month revenue of Beta Drugs Ltd. is ₹ 410.17 Cr, reflecting a 1-year growth of 6.20% and a 3-year CAGR of 19.22%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Beta Drugs Ltd.?

The latest trailing twelve month net profit (PAT) of Beta Drugs Ltd. is ₹ 45.59 Cr, with a 3-year earnings CAGR of 10.38%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Beta Drugs Ltd.?

The trailing twelve month EBITDA of Beta Drugs Ltd. is approximately ₹ 65.57 Cr (based on an operating margin of 15.99%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Beta Drugs Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Beta Drugs Ltd. is 44.21. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Beta Drugs Ltd.?

The debt-to-equity ratio of Beta Drugs Ltd. stands at 0.60. The interest coverage ratio is 4.51x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Beta Drugs Ltd.?

The estimated book value per share of Beta Drugs Ltd. is 242.47 (derived from a P/B ratio of 9.55 and market price of ₹ 2,315.60), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Beta Drugs Ltd.?

The trailing twelve month operating cash flow of Beta Drugs Ltd. is ₹ 31.84 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Beta Drugs Ltd. report consolidated or standalone financials?

Beta Drugs Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.